Prognostic tools | Clinical calculators

Clinical calculators

Find a collection of essential clinical calculators for oncologists and healthcare professionals.

“Statistics are human beings with tears wiped off.”
Paul Brodeur

Epiphany

Classify patients with cancer and pulmonary embolism (PE), whether incidental or symptomatic, according to the risk of serious complications within 15 days.

Agamenon

Predict 12- and 24-month overall survival in patients with histologically confirmed unresectable or metastatic adenocarcinoma of the distal esophagus, gastroesophageal junction (GEJ), and/ or stomach who have received polychemotherapy using two or more drugs as first-line treatment.

Agamenon Triplet

Estimates the effect of adding docetaxel to a first-line with platinum and fluoropyrimidine, in patients with histologically confirmed unresectable or metastatic adenocarcinoma of the distal esophagus, gastroesophageal junction (GEJ), or stomach.

Bayescores

Uses state-of-the-art Bayesian modeling to comprehensively and intuitively assess therapeutic efficacy in published randomized controlled trials.

Cisne

Identify those patients with febrile neutropenia who are seemingly stable in the first hours and who throughout the evolution of their febrile process develop serious, unexpected complications.

Her2

Stratify HER2-positive gastric cancer patients receiving trastuzumab and chemotherapy according to their estimated survival endpoints.

Neobreast

Predicts the global health status of women with non-advanced breast cancer, upon completion of systemic adjuvant therapy.

Neptune

Neuroendocrine neoplasms (NENs) are increasingly prevalent. This calculator aims to estimate patient outcomes using real-world data and clinical factors.

Trasgu

Predict the progression-free survival of patients with well-differentiated gastroenteropancreatic neuroendocrine tumors, with metastases, at the onset of first-line therapy with somatostatin analogues.

Vtrap

Predict prognosis in patients with colorectal cancer who initiate FOLFIRI-aflibercept after progression to oxaliplatin-based regimens.